Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: The ANCHOR study

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Brinton, Eliot A ^a   Ballantyne, Christie M ^b   Bays, Harold E ^c   Kastelein, John J ^d   Braeckman, Rene A ^e   Soni, Paresh N ^e  

^a Utah Foundation for Biomedical Research   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e Amarin Pharma Inc   (United States)

Author keywords

Apolipoprotein B; Cholesterol; Diabetes mellitus; Eicosapentaenoic acid; Hydroxymethylglutaryl CoA reductase inhibitors; Hypertriglyceridemia; Icosapent ethyl; Low density lipoprotein; Triglycerides

Indexed keywords

APOLIPOPROTEIN B; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID ETHYL ESTER; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; AUTACOID; ETHYL EICOSAPENTAENOIC ACID; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; ICOSAPENTAENOIC ACID;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSLIPIDEMIA; GLYCEMIC CONTROL; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; METABOLISM; PHASE 3 CLINICAL TRIAL; TIME; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; EICOSAPENTAENOIC ACID; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INFLAMMATION MEDIATORS; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84880019277     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-100     Document Type: Article

References (41)

1. Crude and age-adjusted percentage of civilian, noninstitutionalized population with diagnosed diabetes 2013, http://www.cdc.gov/diabetes/statistics/prev/national/figage.htm.
2. Ford ES. Trends in the risk for coronary heart disease among adults with diagnosed diabetes in the U.S.: findings from the National Health and Nutrition Examination Survey, 1999-2008. Diabetes Care 2011, 34:1337-1343. 10.2337/dc10-2251, 3114334, 21505207.
3. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006, 29:531-537. 10.2337/diacare.29.03.06.dc05-1254, 16505501.
4. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011, 123:2292-2333. 10.1161/CIR.0b013e3182160726, 21502576.
5. Fruchart JC, Sacks FM, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diab Vasc Dis Res 2008, 5:319-335. 10.3132/dvdr.2008.046, 18958843.
6. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125. 10.1016/S0140-6736(08)60104-X, 18191683.
7. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007, 30:162-172. 10.2337/dc07-9917, 17192355.
8. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 2009, 53:316-322. 10.1016/j.jacc.2008.10.024, 19161879.
9. Nettleton JA, Katz R. n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review. J Am Diet Assoc 2005, 105:428-440. 10.1016/j.jada.2004.11.029, 15746832.
10. Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 2012, 110:984-992. 10.1016/j.amjcard.2012.05.031, 22819432.
11. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421. Third Report of the National Cholesterol Education Program (NCEP).
12. Warnick GR, Albers JJ. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 1978, 19:65-76.
13. Manual of Laboratory Operations LRC Program, Vol. 1: Lipid and Lipoprotein Analysis. DHEW Publication No. (NIH) 75-628. May 1974 1982, Department of Health, Education, and Welfare: Washington, DC, Manual of Laboratory Operations.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419. 10.1007/BF00280883, 3899825.
15. Hartweg J, Farmer AJ, Perera R, Holman RR, Neil HA. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. Diabetologia 2007, 50:1593-1602. 10.1007/s00125-007-0695-z, 17541540.
16. Hartweg J, Perera R, Montori V, Dinneen S, Neil HA, Farmer A. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008, CD003205.
17. Sasaki J, Miwa T, Odawara M. Administration of highly purified eicosapentaenoic acid to statin-treated diabetic patients further improves vascular function. Endocr J 2012, 59:297-304. 10.1507/endocrj.EJ11-0394, 22293584.
18. Mocking RJ, Assies J, Bot M, Jansen EH, Schene AH, Pouwer F. Biological effects of add-on eicosapentaenoic acid supplementation in diabetes mellitus and co-morbid depression: a randomized controlled trial. PLoS One 2012, 7:e49431. 10.1371/journal.pone.0049431, 3509102, 23209576.
19. Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep 2011, 13:474-483. 10.1007/s11883-011-0210-3, 21975919.
20. Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol 2012, 6:5-18. 10.1016/j.jacl.2011.10.018, 22264569.
21. Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999, 22:1971-1977. 10.2337/diacare.22.12.1971, 10587828.
22. Nystrom T. C-reactive protein: a marker or a player?. Clin Sci (Lond) 2007, 113:79-81.
23. McPherson R. Remnant cholesterol: " Non-(HDL-C + LDL-C)" as a coronary artery disease risk factor. J Am Coll Cardiol 2013, 61:437-439. 10.1016/j.jacc.2012.11.009, 23265336.
24. Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013, 61:427-436. 10.1016/j.jacc.2012.08.1026, 23265341.
25. Harris WS, Ginsberg HN, Arunakul N, Shachter NS, Windsor SL, Adams M, Berglund L, Osmundsen K. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997, 4:385-391. 10.1097/00043798-199710000-00011, 9865671.
26. Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007, 29:1354-1367. 10.1016/j.clinthera.2007.07.018, 17825687.
27. Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN. Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). J Clin Lipidol 2012, 6:565-572. 10.1016/j.jacl.2012.07.001, 23312052.
28. Davidson MH, Maki KC, Bays H, Carter R, Ballantyne CM. Effects of prescription omega-3 ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol 2009, 3:332-340. 10.1016/j.jacl.2009.08.001, 21291831.
29. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267.
30. Davidson MH. HDL and CETP Inhibition: Will This DEFINE the Future?. Curr Treat Options Cardiovasc Med 2012, 14:384-390. 10.1007/s11936-012-0191-8, 22723175.
31. Wu JH, Micha R, Imamura F, Pan A, Biggs ML, Ajaz O, Djousse L, Hu B, Mozaffarian D. Omega-3 fatty acids and incident type 2 diabetes: a systematic review and meta-analysis. Br J Nutr 2012, 107:S214-S227. 10.1017/S0007114512001602, 22591895.
32. Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, Clark NG, Franz MJ, Hoogwerf BJ, Lichtenstein AH, Mayer-Davis E, Mooradian AD, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008, 31:S61-S78.
33. GISSI Prevenzione Investigators Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999, 354:447-455. GISSI Prevenzione Investigators.
34. Marchioli R, Barzi F, Bomba E, Chieffo C, Di GD, Di MR, Franzosi MG, Geraci E, Levantesi G, Maggioni AP, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002, 105:1897-1903. 10.1161/01.CIR.0000014682.14181.F2, 11997274.
35. Marchioli R, Marfisi RM, Borrelli G, Chieffo C, Franzosi MG, Levantesi G, Maggioni AP, Nicolosi GL, Scarano M, Silletta MG, et al. Efficacy of n-3 polyunsaturated fatty acids according to clinical characteristics of patients with recent myocardial infarction: insights from the GISSI-Prevenzione trial. J Cardiovasc Med (Hagerstown) 2007, 8:S34-S37.
36. Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010, 363:2015-2026. 10.1056/NEJMoa1003603, 20929341.
37. Kromhout D, Geleijnse JM, De GJ, Oude Griep LM, Mulder BJ, De Boer MJ, Deckers JW, Boersma E, Zock PL, Giltay EJ. n-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes. Diabetes Care 2011, 34:2515-2520. 10.2337/dc11-0896, 3220851, 22110169.
38. Kazemian P, Kazemi-Bajestani SM, Alherbish A, Steed J, Oudit GY. The use of omega-3 poly-unsaturated fatty acids in heart failure: a preferential role in patients with diabetes. Cardiovasc Drugs Ther 2012, 26:311-320. 10.1007/s10557-012-6397-x, 22644698.
39. Oikawa S, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Sasaki J, Hishida H, Itakura H, et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2009, 206:535-539. 10.1016/j.atherosclerosis.2009.03.029, 19447387.
40. Hou L, Lian K, Yao M, Shi Y, Lu X, Fang L, He T, Jiang L. Reduction of n-3 PUFAs, specifically DHA and EPA, and enhancement of peroxisomal beta-oxidation in type 2 diabetic rat heart. Cardiovasc Diabetol 2012, 11:126. 10.1186/1475-2840-11-126, 3490815, 23057715.
41. ORIGIN Trial Investigators n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012, 367:309-318. ORIGIN Trial Investigators.